Rezum therapy for management of frail patients with catheter dependent urinary retention due to benign prostate hyperplasia: A 1 year follow up study.

This study evaluates the one-year outcomes of Rezum therapy, a minimally invasive water vapor thermal treatment, in frail patients with catheter-dependent urinary retention due to benign prostatic hyperplasia (BPH) and a PRISMA-7 questionnaire score of ≥3. Eighty patients with an average prostate volume of 65 mL underwent Rezum treatment under local anesthesia, resulting in significant improvements in International Prostate Symptom Scores (IPSS), reductions in post-void residual urine volume, prostate size, and prostate-specific antigen (PSA) levels over 12 months. The procedure demonstrated a high catheter-free rate (85%) with minimal complications and reduced reliance on BPH medications post-treatment. These findings suggest Rezum therapy as a feasible and effective option for managing urinary retention in frail patients with BPH, though further long-term prospective studies are recommended.